INTRODUCTION
death, cancers, melanoma, cancer, sarcoma, coronavirus disease
CANCERS, MELANOMA, CANCER, CHRONIC DISEASES, PROSTATE, SARCOMA
The advent and widespread adoption of systemic therapies such as immunotherapy and molecular targeted therapy have substantially improved survival rates for patients with advanced melanoma. The current 5‐year survival rate of patients with advanced melanoma receiving therapies such as programmed cell death protein 1 (PD‐1)/cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors and v‐Raf murine sarcoma viral oncogene homologue B (BRAF)/mitogen‐activated protein kinase kinase (MEK) inhibitors ranges from ~34% to 52%.Exercise has been considered an important non‐pharmacological therapy for patients during and/or following cancer treatment. Current guidelines recommend using exercise and physical activity interventions for a range of cancers including breast, prostate, colorectal, lung, haematological and head and neck cancers.The global emergence of coronavirus disease (COVID‐19) has significantly impacted traditional exercise settings and service delivery. Social distancing measures, quarantine and self‐isolation rules had been put in place to protect the population, particularly those with chronic diseases. Patients with cancer,